期刊文献+

全人源抗人干扰素α1b基因工程抗体与抗原的结合表位鉴定

The epitope identification of human interferon α1b against a gene engineering human antibody
下载PDF
导出
摘要 目的鉴定抗原人干扰素α1b(huIFN-α1b)与1株全人源抗体蛋白AIFNa1IgG1的结合表位。方法从正常人分离纯化淋巴细胞并抽提mRNA进行CDNA合成,以CDNA为模板通过PCR扩增得到huIFN-α1b基因,通过重叠延伸PCR法构建huIFN-α1b蛋白29-35位氨基酸残基缺失突变体及点突变体,野生型和突变基因与载体pET30a连接构建重组表达载体,将以上重组表达载体转化大肠杆菌表达宿主E.coli Rosseta(DE3),诱导表达后的huIFN-α1b蛋白及突变体通过Western blot分析其与全人源抗huIFN-α1b基因工程抗体蛋白的结合活性。结果 huIFN-α1b蛋白在E.coli Rosseta(DE3)细胞中成功表达,Western-blot分析表明野生型huIFN-α1b蛋白与抗体结合,29-35位氨基酸缺失与抗体失去结合活性,其中27位的Ser,33位的Asp,34位的Arg,35的His,36位的Asp突变为Gly后,抗体与huIFN-α1b的结合可减弱到不可检测的水平。结论 huIFN-α1b蛋白29-35位氨基酸形成的表位是与抗体AIFNa1IgG1结合的重要表位。 We aim to identify the epitope of human interferon α1b(huIFN-α1b) against a gene engineering human antibody AIFNa1IgG1.Firstly,the huIFN-α1b gene was amplified by PCR technology using CDNA as template.The huIFN-α1b protein mutant with amino acid residues 29-35 deletion and point mutation was build through overlap extension PCR method.The wild-type and mutant huIFN-α1b genes were ligated with expression vector pET30a and transformed into E.coli Rosseta(DE3).The expression of huIFN-α1b and its mutant were analyzed by SDS-PAGE Western blot test.Consequently,the antigen huIFN-α1b and its mutant were successfully expressed in DE3.Western blot test showed that wild-type huIFN-α1b could bind with antibody,but huIFN-α1b mutant with 29-35 deletion could not bind with antibody.The huIFN-α1b mutant with single amino acid mutated to Glycine,such as point mutation of site 27,site 33,site 34,site 35,site 36 from Ser,Asp,Arg,His,and Asp to Gly.The result show that huIFN-α1b epitope of amino acid from site 29 to 35 is the binding site of gene engineering human antibody AIFNa1IgG1.
作者 龚斌 梁米芳
出处 《免疫学杂志》 CAS CSCD 北大核心 2012年第2期157-160,共4页 Immunological Journal
基金 国家863计划(2006AA02A252)
关键词 抗体 全人源抗体 人干扰素ctlb 表位 重叠延伸PCR Antibody Whole human antibody Human interferon cllb Epitope Overlap extension PCR
  • 相关文献

参考文献12

  • 1Domanski P, Colamonici OR. The type I interferon receptor: the long and short of it [J]. Cylokine Growth Faetor Rev, 1996, 7 (2): 143-151.
  • 2Platanias LC, Fish EN. Signaling pathways activated by interferons[J]. Exp Hematol, 1999, 27 (11): 1583-1592.
  • 3Pestka S, Krause CD, Waher MR. Interferons, interferon-like cytokines and their receptors [J]. Immunol Rev, 2004, 202: 8-32.
  • 4Constantinescu SN, Croze E, Murli A, et al. Expression and signaling specificity of the IFNAR chain of the type I interferon receptor complex [J]. Proc Natl Acad Sci USA, 1995, 92 (23): 10487-10491.
  • 5Venna A, Platanias LC. Signaling via the interferon-alpha receptor in chronic myelogenous leukemia ceils [J]. Leuk Lymphoma, 2002, 43 (4): 703-709.
  • 6Aucan C, Walley AJ, Hennig JW, et al. Interferon-alpha receptor-1 (IFNAR 1) variants are associated with protection against cerebral malaria in The Gambia [J]. Genes Immun, 2003, 4 (4): 275-282.
  • 7Quadt SR, Chill JH, Levy R, et al. Determination of the human type I interferon receptor binding site on human interferon-alpha2 by cross saturation and an NMR-hased model of the complex [J]. Protein Sci, 2006, 15 (11): 2656-2668.
  • 8Viscomi GC. Stn-cture-activity of type I interferon [J]. Biotherapy, 1996, 10 (1): 59-85.
  • 9Bonnblom L, Ahn GV, Eloranta ML. Type I interferon and lupus[J]. Curr Opin Rhenmatol, 2009, 21 (5): 471-477.
  • 10Ronnblom L, Elkon KB. Cytokines as therapeutic targets in SLE [J]. Nat Rev Rheumatol, 2010, 6 (6): 339-347.

二级参考文献9

  • 1杜威世,王双,孙志伟,俞炜源.全合成人源性噬菌体抗体库的构建[J].军事医学科学院院刊,2006,30(4):319-322. 被引量:4
  • 2Lee CV,Liang WC,Dennis MS,et al.High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold.J Mol Biol,2004,340(5):1073-1093.
  • 3Knappik A,Ge L,Honegger A,et al.Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides.J Mol Biol,2000,2960)57-86.
  • 4Mather JP.Engineered antibody therapeutics.Adv Drug Deliv Revi,2006,58(5/6):631-632.
  • 5Pascual V,Farkas L,Banchereau J.Systemic lupus erythematosns:all roads lead to type Ⅰ interferons.Curr Opin Immunol,2006,18(6):676-682.
  • 6Roanblom L.Aim GV.An etiopathogenic role for the type Ⅰ IFN system in SLE.Trends immunol,2001,22(8):427-431.
  • 7JBanchereau J,Pascual V.Type I interferon in systemic lupus erythematosus and other autoimmune diseases.Immunity,2006,25(3):383-392.
  • 8Ronnblom L,Alm GV.Systemic lupus erythematosus and the type Ⅰ interferon system.Arthritis Res Ther,2003,5(2):68-75.
  • 9Chantharapai A,Lal J,Huang X,et al.Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon:a candidate therapeutic for IDDM and SLE.Cytokine,2001,15(5):250-260.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部